Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.

← Back to Medmonitor

Medication Type: Mental Health

Mental Health

LYBALVI^™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

Approval Date: May 2021

Note: New Product

A combination antipsychotic and opioid antagonist for the treatment of schizophrenia, bipolar I disorder

« Previous 1 2

Medication Name

Approval Date

Description

LYBALVI^™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

May 2021

Mental Health

A combination antipsychotic and opioid antagonist for the treatment of schizophrenia, bipolar I disorder

Note: New Product

« Previous 1 2

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Medmonitor

Medication Type: Mental Health

LYBALVI™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

Medication Name

Approval Date

Category

Description

LYBALVI™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

LYBALVI^™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

LYBALVI^™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE